KAPA
Kairos Pharma, LTD.
Next earnings ≈ Aug 7, 2026 · est. from filing cadence
$0.35
▼ -6.62%$0.35▼ -45.31%
over 1Y
L $0.35EODHDH $1.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-6.6%
1W-18.8%
1M-32.3%
3M-39.6%
YTD-52.0%
1Y-45.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.16x).
Return on equity -85.9% · latest
Kairos Pharma, LTD. shows limited reported revenue, and -85.9% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$1.71M | -$2.34M | -$5.57M |
| Net income | -$1.81M | -$2.60M | -$5.45M |
| Diluted EPS | -$0.17 | -$0.23 | -$0.30 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$3.00M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-72.7%
FCF yield—
Quality & risk
ROIC (est.)-69.4%
Free cash flow—
Total debt—
Net cash$4.49M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+28.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-042026-06-04open ↗DEFA14AFiling2026-05-26open ↗ARSPeriod ending 2025-12-312026-05-22open ↗DEF 14APeriod ending 2026-05-222026-05-22open ↗8-KPeriod ending 2026-05-182026-05-18open ↗10-QPeriod ending 2026-03-312026-05-13open ↗PRE 14APeriod ending 2026-05-112026-05-11open ↗424B3Filing2026-04-01open ↗424B3Filing2026-04-01open ↗10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-022026-03-02open ↗8-KPeriod ending 2026-02-262026-02-26open ↗
Frequently asked
- Is Kairos Pharma, LTD. (KAPA) a buy?
- KAPA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.16x).
- What is Kairos Pharma, LTD.'s quality score?
- KAPA scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001962011, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 1:02:28 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.